World View

Approximately 25% of active drug development originates from China, with a focus on biologics, cell therapies, and cancer R&D. Despite strong interest from multinational pharmaceutical companies, a financing crunch in the startup space is impacting China's biotech sector.

Check out Scrip’s annual ranking of Asia Pacific biopharma companies for 2024!

The Asia 100 ranking is based on Citeline’s analysis of fiscal year 2022 prescription sales data. For more information contact: Ian.Haydock@citeline.com.

See more content from Scrip Asia 100.